載入中
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
前收盤價
US$82.11
+US$4.83 · +6.25%
盤中時間採用ET。市場資料可能有所延遲。
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
日內區間
目前US$82.11
52週區間
目前US$82.11
盤中時間採用ET。市場資料可能有所延遲。
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
日內區間
目前US$82.11
52週區間
目前US$82.11
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 8.3萬 USD | 2.7萬 USD | 11.1萬 USD | 11.4萬 USD | 9.1萬 USD |
| 毛利 | −8.3萬 USD | −2.7萬 USD | −11.1萬 USD | −11.4萬 USD | −9.1萬 USD |
| 研究與開發 | 1.01億 USD | 7506萬 USD | 101.3萬 USD | 446.4萬 USD | 1383.2萬 USD |
| 銷售、一般及管理費用 | 2132.8萬 USD | 1303.6萬 USD | 617.2萬 USD | 526.3萬 USD | 541.2萬 USD |
| 營業費用 | 1.22億 USD | 8809.6萬 USD | 718.5萬 USD | 972.7萬 USD | 1924.4萬 USD |
| 利息收入 | 1663萬 USD | 586.3萬 USD | 195.7萬 USD | 67.5萬 USD | — |
| 利息支出 | — | 146.8萬 USD | — | — | — |
| 折舊和攤銷 | 8.3萬 USD | 2.7萬 USD | 11.1萬 USD | 11.4萬 USD | 9.1萬 USD |
| 營業利益 | −1.22億 USD | −8812.3萬 USD | −729.6萬 USD | −984.1萬 USD | −1933.5萬 USD |
| 淨利 | −1.05億 USD | −8372.4萬 USD | −533.9萬 USD | −992.6萬 USD | −1932.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$144.56
上漲空間 76.06%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.6億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI1.26億1.28%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM1.03億0.13%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF5452.9萬0.06%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO3596.05萬0.26%139.17億 USD0.24%US$356.78+0.94%
iShares Biotechnology ETFIBB3522.72萬0.33%108.2億 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO2681.49萬0.15%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA2338.68萬0.11%218.24億 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
